Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/53769
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJames, H.en
dc.contributor.authorGillis, D.en
dc.contributor.authorHissaria, P.en
dc.contributor.authorLester, S.en
dc.contributor.authorSomogyi, A.en
dc.contributor.authorCleland, L.en
dc.contributor.authorProudman, S.en
dc.date.issued2008en
dc.identifier.citationJournal of Rheumatology, 2008; 35(4):562-571en
dc.identifier.issn0315-162Xen
dc.identifier.urihttp://hdl.handle.net/2440/53769-
dc.descriptionCopyright © 2008 by The Journal of Rheumatologyen
dc.description.abstractOBJECTIVE: To study genetic polymorphisms in the folate pathway, a site of action of methotrexate (MTX) and sulfasalazine (SSZ), as predictors of efficacy of combination disease modifying antirheumatic drug (DMARD) regimens containing MTX and SSZ in early rheumatoid arthritis (RA). METHODS: Ninety-eight Caucasian patients with early RA received MTX with SSZ, hydroxychloroquine, and folate according to a standardized protocol. Efficacy was evaluated using the Disease Activity Score (DAS28) and European League Against Rheumatism response criteria at 12 months. Nine polymorphisms in 7 genes of the folate pathway were studied. RESULTS: Response to therapy was associated with SLC19A1, MTR, and TYMS polymorphisms. Two favorable allele combinations associated with responder status at 12 months were identified: the MTR 2756A allele in combination with either the SLC19A1 80A allele or the TYMS 3R-del6 haplotype (multivariate analysis, p = 0.0002, p = 0.009 respectively). Seventy of the 72 patients with these allele combinations responded compared to 12/24 patients without [odds ratio (OR) 35.0, 95% confidence interval (CI) 6.9-176, p < 0.0001]. An association with remission (DAS28 < 2.6) was also observed (OR 3.4, 95% CI 1.1-10.0, p = 0.04). When analyzed over 3 years, both the change in DAS score from baseline and the final DAS scores were significantly higher and lower, respectively, with the favorable genotype group (p < 0.0001, p < 0.0001). CONCLUSION: Polymorphic variations in the MTR, SLC19A1, and TYMS genes were associated with better clinical response to combination DMARD regimens containing MTX and SSZ. Allele combinations of these genes may predict response to combination DMARD and assist in treatment decisions in patients with early RA.en
dc.description.statementofresponsibilityHeather M James, David Gillis, Pravin Hissaria, Susan Lester, Andrew A Somogyi, Leslie G Cleland, and Susanna M Proudmanen
dc.description.urihttp://www.jrheum.org/content/35/4/562.abstracten
dc.language.isoenen
dc.publisherJ Rheumatol Publ Coen
dc.subjectHumans; Arthritis, Rheumatoid; Sulfasalazine; Methotrexate; Folic Acid; Hydroxychloroquine; Tetrahydrofolate Dehydrogenase; Antirheumatic Agents; Drug Therapy, Combination; Severity of Illness Index; Predictive Value of Tests; Health Status; Gene Frequency; Genotype; Haplotypes; Polymorphism, Single Nucleotide; Adult; Aged; Middle Aged; Female; Maleen
dc.titleCommon polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritisen
dc.typeJournal articleen
dc.identifier.rmid0020080447en
dc.identifier.pubid43601-
pubs.library.collectionMedicine publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidLester, S. [0000-0003-3013-2701]en
dc.identifier.orcidSomogyi, A. [0000-0003-4779-0380]en
dc.identifier.orcidProudman, S. [0000-0002-3046-9884]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.